Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease
ObjectiveThis study investigates the link between inflammatory markers and liver fibrosis in type 2 diabetes mellitus (T2DM) patients with metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsFrom Oct 2020 to Oct 2024, 769 hospitalized T2DM patients were studied. They were split into...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1556646/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702111427690496 |
|---|---|
| author | Yange Tang Yulong Deng Gengliang Zhang Yanjun Wang Jing Wang Jie Wu Mengjin Gu |
| author_facet | Yange Tang Yulong Deng Gengliang Zhang Yanjun Wang Jing Wang Jie Wu Mengjin Gu |
| author_sort | Yange Tang |
| collection | DOAJ |
| description | ObjectiveThis study investigates the link between inflammatory markers and liver fibrosis in type 2 diabetes mellitus (T2DM) patients with metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsFrom Oct 2020 to Oct 2024, 769 hospitalized T2DM patients were studied. They were split into Control (n=389) and Experimental groups (T2DM with MAFLD, n=380). The Experimental group was further divided based on FIB-4 scores into non-fibrosis (FIB-4< 1.3, n=267), suspected fibrosis (1.3 ≤ FIB-4 ≤ 2.67, n=99), and advanced fibrosis (FIB-4 > 2.67, n=14). Logistic regression identified factors affecting liver fibrosis, while ROC analysis assessed the predictive value of NLR, SIRI, PLR, and PHR for liver fibrosis in T2DM-MAFLD patients.ResultsThe Experimental group showed higher BMI, FPG, TG, TC, LDL-C, ALT, AST, ALB, GGT, and SUA, but lower age, diabetes duration, MPV, and HDL-C (P< 0.05). Compared to non-fibrosis, suspected fibrosis had higher age, diabetes duration, MPV, AST, and NLR, and lower LY, PLR, PHR. Advanced fibrosis featured higher age, AST, NLR, FPG, HbA1c, SIRI, and lower LY, RBC, LDL-C, PLR, PHR, Hb, PLT, and ALB (P< 0.05). Logistic regression identified NLR, SIRI, PLR, and PHR as significant factors for liver fibrosis. ROC analysis showed AUCs of 0.712 (NLR), 0.757 (SIRI), 0.703 (PLR), and 0.806 (PHR) with sensitivities and specificities varying among markers. Optimal cut-offs were 1.573 (NLR), 1.465 (SIRI), 110.819 (PLR), and 185.379 (PHR).ConclusionsNLR, SIRI, PLR, and PHR significantly influence liver fibrosis in T2DM patients with MAFLD, aiding in its diagnosis and management. |
| format | Article |
| id | doaj-art-8c25ab09af2149eb9bbf01b84695f9da |
| institution | DOAJ |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-8c25ab09af2149eb9bbf01b84695f9da2025-08-20T03:17:44ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-04-011610.3389/fendo.2025.15566461556646Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver diseaseYange Tang0Yulong Deng1Gengliang Zhang2Yanjun Wang3Jing Wang4Jie Wu5Mengjin Gu6Department of Endocrinology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Orthopaedics and Traumatology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Endocrinology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Endocrinology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Endocrinology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Endocrinology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, ChinaDepartment of Anesthesiology, Zhengding County People’s Hospital, Shijiazhuang, ChinaObjectiveThis study investigates the link between inflammatory markers and liver fibrosis in type 2 diabetes mellitus (T2DM) patients with metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsFrom Oct 2020 to Oct 2024, 769 hospitalized T2DM patients were studied. They were split into Control (n=389) and Experimental groups (T2DM with MAFLD, n=380). The Experimental group was further divided based on FIB-4 scores into non-fibrosis (FIB-4< 1.3, n=267), suspected fibrosis (1.3 ≤ FIB-4 ≤ 2.67, n=99), and advanced fibrosis (FIB-4 > 2.67, n=14). Logistic regression identified factors affecting liver fibrosis, while ROC analysis assessed the predictive value of NLR, SIRI, PLR, and PHR for liver fibrosis in T2DM-MAFLD patients.ResultsThe Experimental group showed higher BMI, FPG, TG, TC, LDL-C, ALT, AST, ALB, GGT, and SUA, but lower age, diabetes duration, MPV, and HDL-C (P< 0.05). Compared to non-fibrosis, suspected fibrosis had higher age, diabetes duration, MPV, AST, and NLR, and lower LY, PLR, PHR. Advanced fibrosis featured higher age, AST, NLR, FPG, HbA1c, SIRI, and lower LY, RBC, LDL-C, PLR, PHR, Hb, PLT, and ALB (P< 0.05). Logistic regression identified NLR, SIRI, PLR, and PHR as significant factors for liver fibrosis. ROC analysis showed AUCs of 0.712 (NLR), 0.757 (SIRI), 0.703 (PLR), and 0.806 (PHR) with sensitivities and specificities varying among markers. Optimal cut-offs were 1.573 (NLR), 1.465 (SIRI), 110.819 (PLR), and 185.379 (PHR).ConclusionsNLR, SIRI, PLR, and PHR significantly influence liver fibrosis in T2DM patients with MAFLD, aiding in its diagnosis and management.https://www.frontiersin.org/articles/10.3389/fendo.2025.1556646/fullinflammatory markerstype 2 diabetes mellitusmetabolic dysfunction-associated fatty liver diseaseliver fibrosisdiagnosis |
| spellingShingle | Yange Tang Yulong Deng Gengliang Zhang Yanjun Wang Jing Wang Jie Wu Mengjin Gu Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease Frontiers in Endocrinology inflammatory markers type 2 diabetes mellitus metabolic dysfunction-associated fatty liver disease liver fibrosis diagnosis |
| title | Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease |
| title_full | Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease |
| title_fullStr | Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease |
| title_full_unstemmed | Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease |
| title_short | Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease |
| title_sort | inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction associated fatty liver disease |
| topic | inflammatory markers type 2 diabetes mellitus metabolic dysfunction-associated fatty liver disease liver fibrosis diagnosis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1556646/full |
| work_keys_str_mv | AT yangetang inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT yulongdeng inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT gengliangzhang inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT yanjunwang inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT jingwang inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT jiewu inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease AT mengjingu inflammatorymarkersaspredictorsofliverfibrosisintype2diabetespatientswithmetabolicdysfunctionassociatedfattyliverdisease |